
know several children stricken with XLMTM, and even has pictures of many of the little tikes up on his office wall. Mike has presented his work on XLMTM at the past several AANP meetings, including trials using myostatin inhibition, targeted enzyme replacement therapy, and gene therapy on animal models of this disease. The work in this story relates to the gene therapy trial that was recently published in Science Translational Medicine (depicted on the left), for which Mike was the study pathologist. A photomicrograph from the article was even featured on the front page of that prestigious journal. He is continuing to work on these treatment options in preparation for translation to human clinical trials that will occur over the next few years. Congratulations to Dr. Mike Lawlor for splendidly representing neuropathologists in both the lay media and academic press.
No comments:
Post a Comment